Immune complexes containing malondialdehyde (MDA) LDL induce apoptosis in human macrophages

Immune complexes containing malondialdehyde (MDA) LDL induce apoptosis in human macrophages

Copyright © 2017. Published by Elsevier Inc.

Détails bibliographiques
Publié dans:Clinical immunology (Orlando, Fla.). - 1999. - 187(2018) vom: 01. Feb., Seite 1-9
Auteur principal: Virella, Gabriel (Auteur)
Autres auteurs: Wilson, Kelsey, Elkes, Johnathon, Hammad, Samar M, Rajab, Hussein A, Li, Yanchun, Chassereau, Charlyne, Huang, Yan, Lopes-Virella, Maria
Format: Article en ligne
Langue:English
Publié: 2018
Accès à la collection:Clinical immunology (Orlando, Fla.)
Sujets:Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Apoptosis Arteriosclerosis Cardiovascular disease Immune complexes MDA-LDL Matrix metalloproteinases Modified LDL plus... Unstable atherosclerotic plaque Antigen-Antibody Complex Autoantibodies CCL2 protein, human Chemokine CCL2 Cytokines FCGR1A protein, human IL6 protein, human Interleukin-6 Lipoproteins, LDL Receptors, IgG Receptors, Tumor Necrosis Factor, Type I TIMP1 protein, human TNF protein, human Tissue Inhibitor of Metalloproteinase-1 Tumor Necrosis Factor-alpha malondialdehyde-low density lipoprotein, human oxidized low density lipoprotein Malondialdehyde 4Y8F71G49Q CASP3 protein, human EC 3.4.22.- Caspase 3 MMP9 protein, human EC 3.4.24.35 Matrix Metalloproteinase 9 MMP1 protein, human EC 3.4.24.7 Matrix Metalloproteinase 1
LEADER 01000caa a22002652 4500
001 NLM27366154X
003 DE-627
005 20250221225050.0
007 cr uuu---uuuuu
008 231225s2018 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.clim.2017.06.010  |2 doi 
028 5 2 |a pubmed25n0912.xml 
035 |a (DE-627)NLM27366154X 
035 |a (NLM)28689783 
035 |a (PII)S1521-6616(17)30167-5 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Virella, Gabriel  |e verfasserin  |4 aut 
245 1 0 |a Immune complexes containing malondialdehyde (MDA) LDL induce apoptosis in human macrophages 
264 1 |c 2018 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 18.03.2019 
500 |a Date Revised 18.03.2019 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
520 |a Copyright © 2017. Published by Elsevier Inc. 
520 |a Immune complexes (IC) containing predominantly malondialdehyde-LDL and the corresponding autoantibodies (MDA-LDL IC) predict acute cardiovascular events, while IC rich in oxidized LDL (oxLDL IC) predict cardiovascular disease progression. Our objective was to determine mechanisms that could explain these prognostic differences. We compared the effects of the interaction of oxLDL, MDA-LDL and the corresponding IC with human macrophages focusing on apoptosis, metalloproteinases, and proinflammatory cytokines. MDA-LDL IC induced higher degrees of apoptosis, higher levels of caspase-3 expression, and increased expression and release of MMP-1 and TNF compared to MDA-LDL, oxLDL, and oxLDL IC. The pro-apoptotic effects of MDA-LDL IC were inhibited by blocking TNFR 1 or FcγRI. Blocking FcγRI abrogated the induction and expression of MMPs and proinflammatory cytokines by MDA-LDL IC. In conclusion, the interaction of MDA-LDL IC with FcγRI triggers macrophage apoptosis and increased expression and release of TNF and MMP-1, which can lead to the rupture of unstable plaques 
650 4 |a Journal Article 
650 4 |a Research Support, N.I.H., Extramural 
650 4 |a Research Support, Non-U.S. Gov't 
650 4 |a Apoptosis 
650 4 |a Arteriosclerosis 
650 4 |a Cardiovascular disease 
650 4 |a Immune complexes 
650 4 |a MDA-LDL 
650 4 |a Matrix metalloproteinases 
650 4 |a Modified LDL 
650 4 |a Unstable atherosclerotic plaque 
650 7 |a Antigen-Antibody Complex  |2 NLM 
650 7 |a Autoantibodies  |2 NLM 
650 7 |a CCL2 protein, human  |2 NLM 
650 7 |a Chemokine CCL2  |2 NLM 
650 7 |a Cytokines  |2 NLM 
650 7 |a FCGR1A protein, human  |2 NLM 
650 7 |a IL6 protein, human  |2 NLM 
650 7 |a Interleukin-6  |2 NLM 
650 7 |a Lipoproteins, LDL  |2 NLM 
650 7 |a Receptors, IgG  |2 NLM 
650 7 |a Receptors, Tumor Necrosis Factor, Type I  |2 NLM 
650 7 |a TIMP1 protein, human  |2 NLM 
650 7 |a TNF protein, human  |2 NLM 
650 7 |a Tissue Inhibitor of Metalloproteinase-1  |2 NLM 
650 7 |a Tumor Necrosis Factor-alpha  |2 NLM 
650 7 |a malondialdehyde-low density lipoprotein, human  |2 NLM 
650 7 |a oxidized low density lipoprotein  |2 NLM 
650 7 |a Malondialdehyde  |2 NLM 
650 7 |a 4Y8F71G49Q  |2 NLM 
650 7 |a CASP3 protein, human  |2 NLM 
650 7 |a EC 3.4.22.-  |2 NLM 
650 7 |a Caspase 3  |2 NLM 
650 7 |a EC 3.4.22.-  |2 NLM 
650 7 |a MMP9 protein, human  |2 NLM 
650 7 |a EC 3.4.24.35  |2 NLM 
650 7 |a Matrix Metalloproteinase 9  |2 NLM 
650 7 |a EC 3.4.24.35  |2 NLM 
650 7 |a MMP1 protein, human  |2 NLM 
650 7 |a EC 3.4.24.7  |2 NLM 
650 7 |a Matrix Metalloproteinase 1  |2 NLM 
650 7 |a EC 3.4.24.7  |2 NLM 
700 1 |a Wilson, Kelsey  |e verfasserin  |4 aut 
700 1 |a Elkes, Johnathon  |e verfasserin  |4 aut 
700 1 |a Hammad, Samar M  |e verfasserin  |4 aut 
700 1 |a Rajab, Hussein A  |e verfasserin  |4 aut 
700 1 |a Li, Yanchun  |e verfasserin  |4 aut 
700 1 |a Chassereau, Charlyne  |e verfasserin  |4 aut 
700 1 |a Huang, Yan  |e verfasserin  |4 aut 
700 1 |a Lopes-Virella, Maria  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Clinical immunology (Orlando, Fla.)  |d 1999  |g 187(2018) vom: 01. Feb., Seite 1-9  |w (DE-627)NLM098196855  |x 1521-7035  |7 nnns 
773 1 8 |g volume:187  |g year:2018  |g day:01  |g month:02  |g pages:1-9 
856 4 0 |u http://dx.doi.org/10.1016/j.clim.2017.06.010  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_24 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 187  |j 2018  |b 01  |c 02  |h 1-9